http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105163733-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-02 |
| filingDate | 2014-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105163733-B |
| titleOfInvention | Furan ketone compound as kinase inhibitor |
| abstract | The disclosure provides novel furan ketone compound, or its pharmaceutically acceptable salt, solvate or prodrug, as Raf kinase, especially BRAF kinase inhibitor, it is useful therapeutic agent for treating disease relevant to Raf kinases or illness, such as melanoma, cancer and leukaemia.The disclosure additionally provides the method and technique for being used to prepare these novel furan ketone compounds, the pharmaceutical composition containing these furan ketone compounds, and the treatment method using these furan ketone compounds. |
| priorityDate | 2013-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 126.